- Home
- ONB vs ABVX Comparison
ONB vs ABVX Comparison
Compare ONB & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONB
- ABVX
- Stock Information
- Founded
- ONB 1834
- ABVX 2013
- Country
- ONB United States
- ABVX France
- Employees
- ONB N/A
- ABVX N/A
- Industry
- ONB Major Banks
- ABVX
- Sector
- ONB Finance
- ABVX
- Exchange
- ONB Nasdaq
- ABVX Nasdaq
- Market Cap
- ONB 8.1B
- ABVX 6.7B
- IPO Year
- ONB N/A
- ABVX N/A
- Fundamental
- Price
- ONB $20.88
- ABVX $90.53
- Analyst Decision
- ONB Buy
- ABVX Strong Buy
- Analyst Count
- ONB 11
- ABVX 10
- Target Price
- ONB $26.45
- ABVX $103.80
- AVG Volume (30 Days)
- ONB 6.1M
- ABVX 1.0M
- Earning Date
- ONB 10-22-2025
- ABVX 08-11-2025
- Dividend Yield
- ONB 2.69%
- ABVX N/A
- EPS Growth
- ONB 2.73
- ABVX N/A
- EPS
- ONB 1.69
- ABVX N/A
- Revenue
- ONB $2,110,915,000.00
- ABVX $7,073,400.00
- Revenue This Year
- ONB $45.21
- ABVX $4.44
- Revenue Next Year
- ONB $15.25
- ABVX N/A
- P/E Ratio
- ONB $12.29
- ABVX N/A
- Revenue Growth
- ONB 20.70
- ABVX N/A
- 52 Week Low
- ONB $16.83
- ABVX $4.77
- 52 Week High
- ONB $24.49
- ABVX $98.64
- Technical
- Relative Strength Index (RSI)
- ONB 44.80
- ABVX 59.02
- Support Level
- ONB $19.39
- ABVX $90.14
- Resistance Level
- ONB $22.06
- ABVX $94.26
- Average True Range (ATR)
- ONB 0.79
- ABVX 4.00
- MACD
- ONB -0.09
- ABVX -0.58
- Stochastic Oscillator
- ONB 43.85
- ABVX 49.92
About ONB Old National Bancorp
Old National Bancorp with almost $10 billion in assets following its latest acquisition, Old National Bancorp is a financial services bank holding company headquartered in Indiana. Based in Evansville, Ind., Old National owns multiple financial services operations in Indiana, Illinois, and Kentucky. The company provides a group of similar community banking services, including such products and services as commercial, real estate, and consumer loans; deposits; and brokerage, trust, and investment advisory services.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.